New York, May 20, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on May 17, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to its failure to timely file its Form 10-Q for the period ended March 31, 2024, with the Securities and Exchange Commission (the "SEC"), and because the Company remains delinquent in filing its Form 10-K for the fiscal year ended December 31, 2023, it is not in compliance with Nasdaq's contin

New York, April 23, 2024 (GLOBE NEWSWIRE) --  BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on April 19, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (

New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company's 2022 Annual General Meeting of Stockholders (the "Annual Meeting") held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022. At the Annual General Meeting the shareholders voted and approved; 1. The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and quali

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) --  BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023. Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively. Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang hospitals, that are held for sale, were accounted for separately. Net loss for the three months ended September 30, 2023 and 2022 was $3,134,072 and $3,099,662, respectively, whi

NEW YORK, NY, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, ", BIMI", ))), a healthcare products and services provider, today announced its entry into material definitive agreements with certain of its warrant holders, pursuant to which BIMI agreed to buy back an aggregate of 7,066,913 warrants to purchase shares of common stock of the Company from these warrant holders. BIMI agreed to pay $0.30 for each share of common stock underlying the warrant, or an aggregate purchase price of $2,120,073.80 to the warrant holders within three (3) business days (for certain sellers), or two (2) months (for certain other sellers), of the signing of the agreements. The

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) --  BIMI International Medical Inc. (the "Company") today announced that on November 21, 2023, the Company received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the "Third Quarter Form 10-Q"), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Nasdaq letter has no immediate effect on the listing of the Company's shares.

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively. Compared with the same period in 2022, revenue increased by $3,211,558, due to the inclusion of the revenues of Phenix Bio Inc., which was acquired on March 15, 2023. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang h

NEW YORK, NY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Phenix Bio Inc., a wholly owned subsidiary of BIMI International Medical Inc. (NASDAQ:BIMI), a leading global healthcare provider, announces the official launch of its "CUCA 3.0 Product Line through China Duty Free Group's (CDFG) online mini program sales platform. This significant milestone means China Duty Free's 26 million members can now purchase Phenix's products directly from CDFG, solidifying the previous purchase agreement between Phenix and CDFG, which became effective on August 1, 2023. About BIMI International Medical Inc. BIMI International Medical Inc. (NASDAQ:BIMI) is a leading global provider of healthcare servic

NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements in Hong Kong, Taiwan and Macau. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its exclusive distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal su

NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as a distributor responsible for the distribution of Phenix's 17 herbal supplements in Mainland China. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal supplements will be made available to co

4 - BIMI Holdings Inc. (0001213660) (Issuer)

3 - BIMI Holdings Inc. (0001213660) (Issuer)

4 - BIMI Holdings Inc. (0001213660) (Issuer)

4 - BIMI Holdings Inc. (0001213660) (Issuer)

4/A - BIMI Holdings Inc. (0001213660) (Issuer)

4/A - BIMI Holdings Inc. (0001213660) (Reporting)

4/A - BIMI International Medical Inc. (0001213660) (Issuer)

4 - BIMI International Medical Inc. (0001213660) (Issuer)

4 - BIMI International Medical Inc. (0001213660) (Issuer)

4 - BIMI International Medical Inc. (0001213660) (Issuer)

Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 40.0% to $3.99. The market value of their outstanding shares is at $88.6 million. ASLAN Pharma (NASDAQ:ASLN) stock increased by 18.51% to $0.37. The market value of their outstanding shares is at $8.3 million. Talphera (NASDAQ:TLPH) shares increased by 15.18% to $0.9. The company's market cap stands at $15.2 million. Geovax Labs (NASDAQ:GOVX) stock rose 13.15% to $2.15. The market value of their outstanding shares is at $5.4 million. SAB Biotherapeutics (NASDAQ:SABS)

Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia. Nurix Therapeutics shares jumped 12.1% to $17.01 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) rose 89.4% to $6.61 in pre-market trading after surging 24% on Friday. Scinai Immunotherapeutics, last week, received a non-binding Letter of Intent from the European Investment Bank for converting loan into equity. Interactive Strength Inc. (NASDAQ:TR

Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 77.4% to $6.19 during Monday's pre-market session. The company's market cap stands at $3.5 million. ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 35.9% to $0.14. The company's market cap stands at $2.4 million. Venus Concept (NASDAQ:VERO) stock increased by 22.86% to $1.15. The company's market cap stands at $7.3 million. Tharimmune (NASDAQ:THAR) shares moved upwards by 19.4% to $4.0. The company's market cap stands at $3.1 million. TRACON Pharma (NASDAQ:TCON) stock moved upwards by 19.04% to $1.5. The market value of their outstanding shares is at $4.0 million. Kineta (NASDAQ:KA) shares moved upwards by

Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for a loss of 1 cent per share. The company reported quarterly sales of $40.42 million topping estimates of $37.90 million, according to data from Benzinga Pro. AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares jumped 345% to $6.06. SRIVARU Holding Limited (NASDAQ:SVMH) gained 150% to $0.3852 after the company announced it will begin accepting paid reserva

Gainers FibroGen (NASDAQ:FGEN) stock moved upwards by 24.4% to $1.53 during Monday's after-market session. The market value of their outstanding shares is at $152.1 million. Candel Therapeutics (NASDAQ:CADL) stock increased by 8.12% to $9.05. The company's market cap stands at $269.2 million. RAPT Therapeutics (NASDAQ:RAPT) shares moved upwards by 7.53% to $4.28. The market value of their outstanding shares is at $149.3 million. Gritstone Bio (NASDAQ:GRTS) shares increased by 7.24% to $0.79. The market value of their outstanding shares is at $85.4 million. Scholar Rock Holding (NASDAQ:SRRK) shares rose 6.96% to $10.14. The company's market cap stands at $808.7 million. Novo Integrated

BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on May 17, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to its failure to timely file its Form 10-Q for the period ended March 31, 2024, with the Securities and Exchange Commission (the "SEC"), and because the Company remains delinquent in filing its Form 10-K for the fiscal year ended December 31, 2023, it is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing

Gainers VolitionRX (AMEX:VNRX) shares rose 33.6% to $0.8 during Tuesday's regular session. The market value of their outstanding shares is at $65.7 million. Palisade Bio (NASDAQ:PALI) stock increased by 29.81% to $6.4. The company's market cap stands at $5.4 million. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 24.67% to $0.14. The market value of their outstanding shares is at $5.5 million. Protagenic Therapeutics (NASDAQ:PTIX) shares increased by 23.88% to $1.55. The company's market cap stands at $6.8 million. BIMI Intl Medical (NASDAQ:BIMI) stock moved upwards by 23.21% to $1.38. The market value of their outstanding shares is at $19.3 million. NKGen Biotech (NASDAQ:NKGN)

Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) shares moved upwards by 8.4% to $0.65. The market value of their outstanding shares is at $23.2 million. Mustang Bio (NASDAQ:MBIO) shares rose 7.78% to $0.4. The market value of their outstanding shares is at $4.1 million. BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 7.46% to $1.44. The market value of their outstanding shares is at $20.1 million. Allarity Therapeutics (NASDAQ:ALLR) stock increased by 7.14% to $1.65. The company's market cap stands at $3.2 million. China SXT Pharmac

New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company's 2022 Annual General Meeting of Stockholders (the "Annual Meeting") held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022. At the Annual General Meeting the shareholders voted and approved; 1. The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and quali

NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements in Hong Kong, Taiwan and Macau. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its exclusive distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal su

NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as a distributor responsible for the distribution of Phenix's 17 herbal supplements in Mainland China. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal supplements will be made available to co

NEW YORK, NY, Sept. 22, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, ", BIMI", ))), a healthcare products and services provider today announced its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company, as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements throughout the Association of Southeast Asian Nations (ASEAN) 10 member countries. Pursuant to the terms of a sales agreement entered on September 20, 2023, Hao Mu Pte. Ltd., as Phenix's exclusive distributor for the 10 ASEAN member countries, must make annual purchases of at least $5 million in order to maintain its exclusive distributor status.

New York, July 15, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a healthcare products and services provider, today announced the results of the Company's 2022 Annual General Meeting of Stockholders (the "Annual Meeting") held on July 13, 2022 at 11:00 a.m. (Beijing Time), at the offices of the Company, 9th Floor, Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P. R. China. At the Annual Meeting, BIMI: 1. Elected seven nominees to serve as directors of the Company;  2. Approved the adoption of an amended and restated certificate of incorporation which, among other things: (1) requires stockholder

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a healthcare products and services provider, today announced that on May 12, 2022, the Board of Directors of the Company appointed Mr. Fnu Oudom to serve as Chairman of the Board and President of the Company, effective immediately. On May 12, 2022, the Board also elected Ms. Sammi Earn Seok Ang as an independent director of the Company, effective immediately. "Recruiting new directors to improve diversity and provide global perspective to the Board is a recently initiated action to enhance BIMI's corporate governance. We believe our new chairman's leadership and connectio

NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a healthcare products and services provider, today announced that it has appointed Mr. Fnu Oudom as a director of the Company effective May 9, 2022, to fill a vacancy that recently occurred as the result of the resignation of a director. Mr. Fnu Oudom has worked at FCCC Inc., a US company focused on strategic investments and acquisitions in a variety of industries, since April 2021. He was Chairman of the Board of the Time Chain Group, a pharmaceutical and nutritional product research & development and distribution company, from March 2015 to March 2021. From May 2018 to D

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a leading healthcare products and services provider in China, today announced the appointment of Amy Xue as the Company's new Chief Financial Officer, effective July 15, 2021. Xue is a CPA and ACCA certified accountant and experienced senior finance executive. Prior to her appointment as BIMI's Chief Financial Officer, she served as CFO at iFresh, Inc. (NASDAQ:IFMK) between March 2020 and June 2021. She has also served as the CFO of Goldenbridge Acquisition Ltd. since March 2020 and is also the Audit Committee Chairwoman at MingZhu Logistics Holdings Limited (NASDAQ:YGMZ)

NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- BOQI International Medical Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), a leading healthcare products and services provider in China, today announced the results of the Company's 2021 Annual General Meeting of Stockholders (the "Annual Meeting") held on June 15, 2021 at 9:00 a.m. (Beijing Time), at Yuzhou Hotel, 168 Yuzhou Road, Yuzhong District, Chongqing, China. At the Annual Meeting, BOQI International Medical Inc.: 1.     Elected the seven nominees named in the accompanying proxy statement to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been duly elected and

SC 13D/A - BIMI Holdings Inc. (0001213660) (Subject)

SC 13D/A - BIMI International Medical Inc. (0001213660) (Subject)

SC 13D - BIMI International Medical Inc. (0001213660) (Subject)

SC 13D/A - BIMI International Medical Inc. (0001213660) (Subject)

SC 13D - BIMI International Medical Inc. (0001213660) (Subject)

SC 13G/A - BIMI International Medical Inc. (0001213660) (Subject)

SC 13G/A - BIMI International Medical Inc. (0001213660) (Subject)

SC 13G - BOQI International Medical, Inc. (0001213660) (Subject)